The development of tafamidis???the first disease-modifying agent targeting the underlying cause of a human amyloid disease ???was built on years of basic scientific research, funded by institutions including the National Institutes of Health (NIDDK), the Skaggs Institute for Chemical Biology, and The Lita Annenberg Hazen Foundation.